From Nasdaq: 2025-02-13 07:51:03

Shares of Gilead Sciences Inc have surpassed the average analyst target price of $101.00, now trading at $103.31/share. Analysts may react by either downgrading on valuation or adjusting their target to a higher level based on fundamental business developments. There are 26 different analyst targets for Gilead Sciences Inc, with a standard deviation of $12.821. Investors are urged to reassess the company as it crosses the average target price. Current analyst ratings breakdown shows 17 strong buy ratings, 12 hold ratings, and an average rating of 1.83. This data is provided by Zacks Investment Research via Quandl.com.



Read more at Nasdaq: GILD Crosses Above Average Analyst Target